Clinical Trials Sponsored by Valencia Technologies Corporation

Total 65 results

Valencia Technologies Corporation

Active, not recruiting

Effectiveness of eCoin at Sensory and Subsensory Amplitudes (ESSENCE)

Urge Incontinence

United States
Valencia Technologies Corporation

Completed

eCoin for OAB Feasibility Follow-on Study

Overactive Bladder | Urge Incontinence | Urinary Urge Incontinence | Incontinence, Urinary

United States, New Zealand
Valencia Technologies Corporation

Recruiting

A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE) (RECIPE)

Overactive Bladder | Urge Incontinence | Urinary Urge Incontinence | Incontinence, Urinary

United States
Valencia Technologies Corporation

Active, not recruiting

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

Overactive Bladder | Urge Incontinence | Urinary Urge Incontinence | Incontinence, Urinary

United States
Valencia Technologies Corporation

Completed

eCoin Tibial Nerve Stimulation for OAB

Urgency Urinary Incontinence

United States, New Zealand
Valencia Technologies Corporation

Withdrawn

Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.

Resistant Hypertension
Silq Technologies Corporation

Recruiting

Evaluation of the Novel Silq ClearTract Catheter in Patients With Chronic Urinary Retention

Catheter Infection | Catheter Blockage | Catheter Related Complication | Catheter Calcification

United States
Silq Technologies Corporation

Active, not recruiting

Randomized Study of Silq Urinary Catheter

UTI | Biofilm Formation

United States
Dynavax Technologies Corporation

Unknown

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

End Stage Renal Disease on Dialysis (Diagnosis)

United States
Dynavax Technologies Corporation

Completed

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

Hepatitis B, Chronic

Poland
Dynavax Technologies Corporation

Terminated

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

Rhinitis, Allergic, Seasonal

United States
Dynavax Technologies Corporation

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Healthy

United States
Dynavax Technologies Corporation

Completed

Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine

Hepatitis B

Germany, Canada
Dynavax Technologies Corporation

Completed

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

Chronic Kidney Disease

United States
Dynavax Technologies Corporation

Completed

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Healthy

United States
Dynavax Technologies Corporation

Completed

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

Healthy

United States, Canada
Dynavax Technologies Corporation

Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Herpes Zoster | Vaccine-Preventable Diseases | Shingles

Australia
Dynavax Technologies Corporation

Completed

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease

United States
Dynavax Technologies Corporation

Completed

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Advanced Non Small Cell Lung Cancer

United States
Dynavax Technologies Corporation

Completed

Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

Hepatitis B

United States
Dynavax Technologies Corporation

Terminated

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
Dynavax Technologies Corporation

Completed

An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber

Rhinitis, Allergic, Seasonal

Canada
Dynavax Technologies Corporation

Terminated

A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

Hepatitis B

Canada
Dynavax Technologies Corporation

Completed

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Hepatitis B

United States
Dynavax Technologies Corporation

Terminated

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

B-cell Lymphoma

United States
Dynavax Technologies Corporation

Completed

Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

End Stage Renal Disease

Germany
Life Technologies Corporation

Completed

Clinical Protocol SeCore, uTYPE and 3500 Dx System

Human Leukocyte Antigens (HLA)
Medicis Technologies Corporation

Completed

Subcutaneous Contouring Using High Intensity Focused Ultrasound

Body Sculpting

Canada
Achros Health Technologies Corporation

Unknown

Proof of Concept Trial to Confirm That the Recovery of Patients Treated in the Intensive Care Unit Requiring Mechanical Ventilation is Beneficially Affected by the Environmental Simulation of Daytime and Night Time Alternation as Well as by the Nutrition Protocol Corresponding to the Daily Rhythm

Critical Illness | Mechanical Ventilation

Hungary
University of Valencia
Baxter Healthcare Corporation

Completed

Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry

Hemophilia A, Congenital

Spain
Yale University
Anteris Technologies Corporation

Recruiting

Defining Exercise Hemodynamics and Function After Transcatheter Aortic Valve Replacement (DEFINE-TAVR) Study. (DEFINE-TAVR)

Aortic Valve Stenosis

United States
AbSolutions Med Inc.
Cogent Technologies Corporation

Recruiting

Abdominal Wall Closure After Laparotomy in Oncologic Surgery (REBUILD)

Laparotomy

Colombia
Dynavax Technologies Corporation
Baylor Research Institute

Completed

A Study of the Immune Response to Heplisav in Healthy Older Adults

Hepatitis B

United States
Empirical Technologies Corporation
University of Virginia

Completed

A-line/CareTaker Comparison Study in ICU Patients

Blood Pressure
Dynavax Technologies Corporation
PPD; Synteract, Inc.

Completed

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C

Poland
AbSolutions Med Inc.
Cogent Technologies Corporation

Not yet recruiting

The REBUILD Trial: Closure of the Abdominal Wall

Surgical Incision

Israel
John T. Nosek

Completed

Expert Guiding Technology to Help Individuals With Developmental Challenges Build Life and Vocational Skills

Intellectual Disability | Autism Spectrum Disorder

United States
University of Louisville
Dynavax Technologies Corporation

Withdrawn

Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection

Hepatitis B Virus
General University Hospital of Valencia
Boston Scientific Corporation

Completed

Clinical Decision Support System (CDSS) in Neurostimulation Therapy (CDSS)

Failed Back Surgery Syndrome
China Medical University Hospital
HIWIN Technologies Corporation

Unknown

Robot-assisted Gait Training for Patients With Stroke

Cerebrovascular Accident

Taiwan
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Incyte Corporation

Active, not recruiting

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Cancer | Recurrent Epithelial Ovarian Cancer | Recurrent Peritoneal Cancer

United States, Canada
Dynavax Technologies Corporation
Merck Sharp & Dohme LLC

Terminated

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic Melanoma | Head Neck Cancer

United States, Germany, New Zealand, Australia
Haemonetics Corporation
ClinStatDevice; Boston Healthcare Technologies Consultants, LLC

Completed

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

Surgery

United States
Dynavax Technologies Corporation
United States Department of Defense

Active, not recruiting

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Vaccine-Preventable Diseases | Plague | Plague, Pneumonic

United States
Ottawa Heart Institute Research Corporation
PAL Technologies Ltd.

Completed

Sedentary Intervention Trial in Cardiac Rehabilitation (SIT-CR)

Coronary Artery Disease

Canada
Dynavax Technologies Corporation
PPD, Part of Thermo Fisher Scientific

Active, not recruiting

DV2-HBV-27: Observational Pregnancy Registry (HBV-27)

Pregnant

United States
Inoveon Corporation
National Eye Institute (NEI); LKC Technologies, Inc.

Completed

RETeval Study for Diabetic Retinopathy

Diabetic Retinopathy

United States
Herz-Zentrums Bad Krozingen
Boston Scientific Corporation; CryoCath Technologies Inc.

Unknown

A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy (CRYO-RF)

Atrial Fibrillation Ablation

Germany
Infoscitex Corporation
Liberating Technologies, Inc.; Telemedicine & Advanced Technology Research...

Unknown

Evaluation of a Pro-Active Dynamic Accommodating Socket (PADS)

Amputation

United States
National Institute of Allergy and Infectious Diseases...
Dynavax Technologies Corporation

Active, not recruiting

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B (BEe-HIVe)

HIV Infection | Hepatitis B

United States, Haiti, Botswana, Philippines, Thailand, Brazil, Kenya, Malawi, India, South Africa, Uganda, Vietnam

Clinical Trials Sponsored by Valencia Technologies Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations